A Randomized Double-blind Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- Acronyms stelara
- Sponsors Janssen Research & Development
- 07 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 2 Jan 2019.
- 22 Feb 2017 Planned End Date changed from 1 Jul 2021 to 1 Mar 2023.
- 10 Feb 2017 Status changed from not yet recruiting to recruiting.